Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has been given an average recommendation of “Buy” by the eight analysts that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $6.00.
A number of analysts recently weighed in on TNXP shares. ValuEngine lowered shares of Tonix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, June 2nd. B. Riley began coverage on Tonix Pharmaceuticals in a report on Wednesday, June 6th. They issued a “buy” rating and a $8.00 price target for the company. Brookline Cap M reaffirmed a “buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, May 1st. Roth Capital reaffirmed a “neutral” rating and issued a $1.00 price target (down from $6.00) on shares of Tonix Pharmaceuticals in a report on Friday, July 27th. Finally, Brookline Capital Management reaffirmed a “buy” rating on shares of Tonix Pharmaceuticals in a report on Tuesday, May 1st.
TNXP stock opened at $1.05 on Friday. Tonix Pharmaceuticals has a fifty-two week low of $0.89 and a fifty-two week high of $5.11. The company has a market cap of $9.51 million, a P/E ratio of -0.36 and a beta of 2.57.
In other Tonix Pharmaceuticals news, Director Ernest Mario purchased 16,500 shares of the stock in a transaction that occurred on Monday, June 25th. The stock was purchased at an average cost of $4.48 per share, with a total value of $73,920.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Sullivan acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, June 14th. The stock was purchased at an average cost of $3.97 per share, with a total value of $39,700.00. Following the completion of the acquisition, the insider now directly owns 20,482 shares of the company’s stock, valued at approximately $81,313.54. The disclosure for this purchase can be found here. Insiders purchased 42,300 shares of company stock valued at $170,237 over the last ninety days. 4.12% of the stock is currently owned by corporate insiders.
An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Renaissance Technologies LLC grew its position in Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) by 90.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,800 shares of the company’s stock after acquiring an additional 35,600 shares during the quarter. Renaissance Technologies LLC owned about 0.96% of Tonix Pharmaceuticals worth $258,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 13.52% of the company’s stock.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.
Featured Story: Stock Symbol
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.